Meta-analysis of randomized trials: Clopidogrel is better than aspirin for the secondary prevention of cardiovascular events.
31 Mar, 2022 | 08:31h | UTCCommentary: Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention – TCTMD
Commentary on Twitter
Happy to share our paper in @ESC_Journals. In this meta-analysis of randomized trials, we found that as compared with aspirin, P2Y12i was associated with 11% and 19% reduction in MACE and MI respectively. https://t.co/Y3Gstzgfu6
— Devika Aggarwal (@devikagg) March 30, 2022